Adverum Biotech
Adverum Biotechnologies (Nasdaq: ADVM) is a clinical-stage gene therapy company targeting unmet medical needs for serious ocular and rare diseases. Adverum is evaluating its novel gene therapy candidate, ADVM-022, as a one-time, intravitreal injection for the treatment of its lead indication, wet ag...Read more
Org chart
Teams
View all
Discover similar companies
Sigilon Therapeutics
Post IPO Equity • Cambridge, United States
Dyne Therapeutics
Post IPO Equity • Cambridge, United States
Jounce Therapeutics
Post IPO Equity • Cambridge, United States
Ovid Therapeutics
Post IPO Equity • New York, United States
Arbutus Biopharma
Post IPO Equity • Warminster, United States
Passage Bio
Post IPO Equity • Philadelphia, United States
Krystal Biotech
Post IPO Equity • Pittsburgh, United States
Century Therapeutics
Post IPO Equity • Philadelphia, United States
Magenta Therapeutics
Post IPO Equity • Cambridge, United States
Celularity
Post IPO Equity • Florham Park, United States
Axsome Therapeutics
Post IPO Equity • New York, United States
Stemline Therapeutics
Post IPO Equity • New York, United States
helps you hire
great candidates
It’s free to use - try it out today.